Swedish Orphan Biovitrum ABSWOBY 67 WACC % is 8.45% as of Jun. 25, 2026, which is 23% above its 10-year median of 6.85. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.17 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,020 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 54.61% on this metric.
As of today (2026-06-25), Swedish Orphan Biovitrum AB's weighted average cost of capital is 8.45%%. Swedish Orphan Biovitrum AB's ROIC % is 1.93% (calculated using TTM income statement data).
Swedish Orphan Biovitrum AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.
*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
For a comprehensive WACC calculation, please access the WACC Calculator.
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) WACC % Explanation
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Swedish Orphan Biovitrum AB's weighted average cost of capital is 8.45%%. Swedish Orphan Biovitrum AB's ROIC % is 1.93% (calculated using TTM income statement data).
Swedish Orphan Biovitrum AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.
*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
Related Terms
Swedish Orphan Biovitrum AB WACC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB WACC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's WACC % distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Swedish Orphan Biovitrum AB's market capitalization (E) is $16033.374 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, Swedish Orphan Biovitrum AB's latest one-year quarterly average Book Value of Debt (D) is $1491.6348 Mil.
a) weight of equity = E / (E + D) = 16033.374 / (16033.374 + 1491.6348) = 0.9149
b) weight of debt = D / (E + D) = 1491.6348 / (16033.374 + 1491.6348) = 0.0851
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 2.7446%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Swedish Orphan Biovitrum AB's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 2.7446% + 1 * 6% = 8.7446%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2026, Swedish Orphan Biovitrum AB's interest expense (positive number) was $79.02 Mil. Its total Book Value of Debt (D) is $1491.6348 Mil.
Cost of Debt = 79.02 / 1491.6348 = 5.2975%.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = -31.81 / 67.528 = -47.11%, which is less than 0%. Therefore it's set to 0%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (SWOBY) has a WACC % of 8.45% as of Jun. 25, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is 23% above median its historical median of 6.85. Over the past decade, Swedish Orphan Biovitrum AB's WACC % has ranged from 5.23 to 8.53. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #463 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 45.4%.
Is Swedish Orphan Biovitrum AB's WACC % too high?
Swedish Orphan Biovitrum AB's current WACC % of 8.45% is 23% above median its 10-year median of 6.85. Over the past 10 years, this metric has ranged from a low of 5.23 to a high of 8.53. The Drug Manufacturers industry median WACC % is 8.90. Swedish Orphan Biovitrum AB's value of 8.45% is 5% below this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #463 out of 1020 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's WACC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #463 out of 1020 companies for WACC %. This puts Swedish Orphan Biovitrum AB in the upper half of its industry. The industry median WACC % is 8.90. Swedish Orphan Biovitrum AB's value of 8.45% is 5% below this benchmark. Historically, Swedish Orphan Biovitrum AB's own WACC % has ranged from 5.23 to 8.53 over the past decade. While the company's 10-year median is 6.85 vs. the industry median of 8.90, Swedish Orphan Biovitrum AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Drug Manufacturers company?
The median WACC % among Drug Manufacturers companies is 8.90, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current WACC % of 8.45% is 5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median WACC % is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current WACC % is 8.45%, which is 23% above median its own 10-year median of 6.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.17, compared to a current price of $23.18 — trading 35% above its estimated fair value. The current WACC % is 8.45%, which is 23% above median its 10-year median of 6.85 and 5% below the Drug Manufacturers industry median of 8.90. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current WACC % is 8.45% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.18 is trading 35% above its estimated GF Value™ of $17.17.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
WACC %: 8.45% (23% above median its 10-year median of 6.85)
GF Value™: $17.17 vs. price of $23.18 (35% above fair value)
Industry Position: 5% below the Drug Manufacturers median (#463 of 1020)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
